← boardnext 2026-11next 2027-08-16
VIR
Vir Biotechnology, Inc.distress 4/10 · elevated risk$9.25-1%today-17% from 52w high
Infectious Disease 1Nephrology 1
Lead: Viral Hepatitis · target HBV · est. market ~$10B (approx, global)
Revenue
pre-revenue
Liquidity
$803M
Runway
1.8 yrs
Shares 1y
+21%
Price & events
+25.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.1%
1D
-1.6%
1W
-9.0%
1M
-10.6%
3M
+22.4%
6M
+58.1%
1Y
-9.3%
2Y
-74.9%
5Y
-65.4%
All
Overview
- Market Cap
- $1.56B
- Volume
- 52.29K
- 52 Week Range
- $4.28 – $11.09
- Total Shares
- 168.65M
- Float Shares
- 128.76M
- Short %
- 11.52%
- % Held by Insiders
- 6.59%
- % Held by Institutions
- 80.76%
- RVOL
- 0.03x
- Beta
- 1.62
Pipeline stages · 2 programs
Tobevibart, Elebsiran
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VIR-2218, VIR-3434, NRTI
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 9 trials · 7 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11 Estimated 50% readout ~2026-12-16 | Phase 2 | Tobevibart, Elebsiran, Bulevirtide | Viral Hepatitis | — | active not recruiting |
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | Tobevibart, Elebsiran, Bulevirtide | Viral Hepatitis | — | recruiting |
| 2026-12-31 Estimated 50% readout ~2027-03-16 | Phase 3 | Tobevibart, Elebsiran | Viral Hepatitis | — | active not recruiting |
| 2027-08-16 Estimated 50% readout ~2027-09-30 | Phase 1/2 | VIR-5818, pembrolizumab | Locally Advanced or Metastatic HER2-Expressing Cancers | — | recruiting |
| 2027-09-29 Estimated 50% readout ~2027-10-29 | Phase 1 | VIR-5500 | Hormone-refractory Prostate Cancer | — | recruiting |
Show all 9 trials · 4 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-08 Estimated 50% readout ~2029-08-31 | Phase 1 | VIR-5525, Pembrolizumab | Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR | — | recruiting |
| 2031-11 Estimated 50% readout ~2031-12-16 | Phase 2 | VIR-2218, VIR-3434, NRTI | Hepatitis D, Chronic | — | active not recruiting |
| 2026-03-16 | Phase 2 | VIR-2218, VIR-3434, PEG-IFNα | Hepatitis B, Chronic | 244 | completed |
| 2025-03-01 | Phase 1 | VIR-2218 | Renal Impairment | 28 | completed |
Catalyst news & presentations · 9
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- February 26, 2026conferencedata presentationsecondaryPhase 1VIR-5500 · Updated Phase 1 results presented at ASCO GU 2026SEC 8-K
- 2026-02-19partnershipVIR-5500 · Global collaboration with Astellas; Vir Bio receives $335M upfront and near-term payments, up to $1.37B in milestones, and double-digit royalties.SEC 8-K
- January 14, 2026 at 3:45 p.m. PTconferencedata presentationsecondaryPresentation at 44th Annual J.P. Morgan Healthcare Conference.SEC 8-K
- 2025-12-16partnershiptobevibart+elebsiran · Exclusive license to Norgine for commercial rights in Europe, Australia, New Zealand for CHD.SEC 8-K
- July 24, 2025trial initiationsecondaryPhase 1VIR-5525 · First patient dosed in Phase 1 clinical trial of VIR-5525, a dual-masked T-cell engager targeting EGFR.SEC 8-K
- May 9, 2025conferencedata presentationsecondaryPhase 2tobevibart+elebsiran · 24-week post-end of treatment data from Part B of MARCH Phase 2 study presented at EASL Congress 2025SEC 8-K
- January 8, 2025conferencedata presentationsecondaryPhase 1VIR-5500 · Presenting initial Phase 1 data from dual-masked T-cell engager VIR-5500.SEC 8-K
- 2024-09-09partnershipObtained exclusive worldwide license from Sanofi for three clinical-stage masked T-cell engagers and protease-cleavable masking platform; upfront $100M plus $75M escrowed milestone.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $22 (+133% upside) · 9 analysts
- 2026-06-11Morgan StanleyOverweight
- 2026-06-03Leerink PartnersOutperform
- 2026-03-04HC Wainwright & Co.Buy
- 2026-02-25BarclaysOverweight
- 2026-02-24Evercore ISI GroupOutperform
- 2026-02-24NeedhamBuy
Competitors — HBV
- ALGSAligos Therapeutics, Inc.$217M · D3
Recent news
- 2026-07-23VIR Q2'26 Earnings: revenue estimate is 135.88M USD - TradingView
- 2026-07-23Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results - BioSpace
- 2026-07-23Vir Biotechnology to host conference call for Q2 2026 results - scanx.trade
- 2026-07-22Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results - Business Wire
- 2026-07-22Unnatural Products Appoints Finance Leader Neera Ravindran, M.D., M.B.A., as Chief Financial Officer - GlobeNewswire
- 2026-07-18Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-18Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-17Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.